DK0759302T3 - Middel mod rheumatoid arthritis - Google Patents

Middel mod rheumatoid arthritis

Info

Publication number
DK0759302T3
DK0759302T3 DK95913319T DK95913319T DK0759302T3 DK 0759302 T3 DK0759302 T3 DK 0759302T3 DK 95913319 T DK95913319 T DK 95913319T DK 95913319 T DK95913319 T DK 95913319T DK 0759302 T3 DK0759302 T3 DK 0759302T3
Authority
DK
Denmark
Prior art keywords
remedy
rheumatoid arthritis
monoclonal antibody
antibody recognizing
arthritis
Prior art date
Application number
DK95913319T
Other languages
English (en)
Inventor
Tadashi Nishida
Sachiko Miyake
Ko Okumura
Hideo Yagita
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of DK0759302T3 publication Critical patent/DK0759302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95913319T 1994-04-26 1995-03-22 Middel mod rheumatoid arthritis DK0759302T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8825194 1994-04-26
PCT/JP1995/000527 WO1995028961A1 (en) 1994-04-26 1995-03-22 Remedy for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
DK0759302T3 true DK0759302T3 (da) 2000-11-13

Family

ID=13937651

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95913319T DK0759302T3 (da) 1994-04-26 1995-03-22 Middel mod rheumatoid arthritis

Country Status (9)

Country Link
US (1) US5855888A (da)
EP (1) EP0759302B1 (da)
AT (1) ATE195428T1 (da)
DE (1) DE69518415T2 (da)
DK (1) DK0759302T3 (da)
ES (1) ES2151054T3 (da)
GR (1) GR3034200T3 (da)
PT (1) PT759302E (da)
WO (1) WO1995028961A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934420T2 (de) * 1998-10-07 2007-09-27 Lennart Lindbom Anti-entzündliche alpha2, beta1 integrin-verwandte substanzen oder antikörper
CN1332714C (zh) * 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
IL146508A0 (en) * 1999-06-01 2002-07-25 Biogen Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6146639A (en) * 1999-07-26 2000-11-14 Merich Nick Arthritis, muscle pain, and dry skin remedy
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
US20030013107A1 (en) * 2001-06-07 2003-01-16 Rigel Pharmaceuticals, Incorporated Alpha 2 integrin: modulators of lymphocyte activation
EP3023497A1 (en) * 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
MX2008014793A (es) * 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
CA2840175C (en) * 2011-05-19 2021-11-16 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
CA2114015C (en) * 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy

Also Published As

Publication number Publication date
EP0759302B1 (en) 2000-08-16
PT759302E (pt) 2001-01-31
WO1995028961A1 (en) 1995-11-02
EP0759302A4 (en) 1997-11-19
ES2151054T3 (es) 2000-12-16
US5855888A (en) 1999-01-05
ATE195428T1 (de) 2000-09-15
EP0759302A1 (en) 1997-02-26
DE69518415D1 (de) 2000-09-21
DE69518415T2 (de) 2001-01-25
GR3034200T3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DK0759302T3 (da) Middel mod rheumatoid arthritis
ITMI921522A0 (it) Apparato di lavaggio e sterilizzazione di tappi di gomma, o simili impiegabili in confezioni farmaceutiche
NL300098I1 (nl) Thiophene sulfonamides useful as carbonic anhydrase inhibitors.
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ATE138569T1 (de) Topisch anzuwendendes arzneimittel enthaltend ketoprofenlysinat
FI961525A0 (fi) Uusi emulsioformulaatio
ZA969130B (en) Diagnostics and treatments of periodontal disease
DE69400338D1 (de) Depigmentierendes Mittel zur gleichzeitigen Behandlung von Hautoberschichten und Hauttiefschichten
FI893159A0 (fi) Laite ja menetelmä terveydenhuollossa syntyvien ongelmajätteiden käsittelemiseksi
BR9406292A (pt) Complexo de inclusão de taxol ou taxotere ou extrato de taxus formados com ciclodextrinas sua preparação e uso
PT615751E (pt) Utilizacao de antagonistas de taquinina no tratamento da emese
DE59104380D1 (de) Vorrichtung zum Bilden von Reihen und Lagen von Flaschen.
ATE433339T1 (de) Parasympathikomimetikum und parasympathikolytikum enthaltendes tts
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
TNSN95055A1 (fr) Un article absorbant jetable-methode et appareillage pour sa fabrication
FR2700472B1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
SE9404331L (sv) Förfarande för sträckning av en materialbana vid framställning av vätskeabsorberande alster och anordning för materialbanans sträckning
ES2187618T3 (es) Utilizacion de compuestos de urea y de tiourea para la eliminacion o desintoxicacion de superantigenos de fluidos corporales.
NO883063L (no) Fremgangsmaate, anordning og sett for maaling av vevplasminogenaktivator-aktivitet.
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции